Weber J, Cheingsong-Popov R, Panagiotidi C, Shaunak S, Beddows S, Bowcock S, Aromstam A; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 153 (abstract no. S.A.286).
Dept of Infectious Diseases and Dept of Haematology, Royal Postgraduate Medical School, London W12 OHS, UK
OBJECTIVE: To quantify the humoral response to HIV proteins at sero-conversion, and to examine the relationship between the titre and function of the antibodies to clinical outcome at 84 months. METHODS: 88 HIV seroconverting haemophiliacs were examined by ELISA assays for titre of antibody to p24 (gag), p27 (nef) and gp120 (env). Antibody function was examined by HIV neutralisation and blocking, srCD4/gp120 binding inhibition and for FcR mediated enhancement. Subjects were classified clinically by CDC stage at October, 1989. RESULTS: Subjects who sero-converted with a high titre anti-p24 at first sero-positive serum showed a prolonged survival time by the Kaplan-Meyer analysis, p= 0.008. Anti-nef antibodies were non-discriminatory. High titre anti-gp120 antibodies at sero-conversion were associated with more rapid progression to AIDS p=0.025. The high titre anti-gp120 did not correlate significantly with neutralisation titre, or with CD4/gp120 binding inhibition and there was no evidence of FcR mediated enhancement. CONCLUSION: Quantitation of the primary humoral response to gag and env proteins at seroconversion defines the clinical outcome of HIV infection at 84 months, in haemophiliac subjects. This suggests that immune containment of HIV infection is possible, although the mechanism is unknown and breathrough seems to occur.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antigens, CD4
- Gene Products, env
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Envelope Protein gp120
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- Hemophilia A
- immunology
Other ID:
UI: 102196081
From Meeting Abstracts